RBC Capital analyst Luca Issi reiterates Caribou Biosciences (NASDAQ:CRBU) with a Outperform and maintains $14 price target.
- Headlines
- RBC Capital Reiterates Outperform on Caribou Biosciences, Maintains $14 Price Target
RBC Capital Reiterates Outperform on Caribou Biosciences, Maintains $14 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Price
Unlock the Full List
Latest
10:49
The State Administration for Market Regulation: Speed up the development of key standards for 2025, supporting greater effectiveness in the "two new" initiatives.
10:45
The State Administration for Market Regulation will focus on key areas such as platform economy, livelihood protection, and natural monopolies to strengthen antitrust enforcement.
10:44
Trump: A meeting with Putin is being arranged.